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Phosphorylation of the herpes simplex virus (HSV) VP22 protein is regulated by cellular kinases and the UL13 viral kinase, but the sites
at which these enzymes induce phosphorylation of HSV-2 VP22 are not known. Using serine-to-alanine mutants to map phosphorylation
sites on HSV-2 VP22 in cells, we made three major observations. First, phosphorylation by a cellular kinase mapped to serines 70, 71, and/or
72 within CKII consensus sites analogous to previously identified phosphorylation sites in HSV-1 VP22. Second, we mapped UL13-
mediated phosphorylation of HSV-2 VP22 to serines 28 and 34, describing for the first time UL13-dependent phosphorylation sites on VP22.
Third, previously identified VP22-associated cellular kinase sites in HSV-1 VP22 (serines 292 and 294) were not phosphorylated in HSV-2
VP22 (serines 291 and 293). VP22 expressed alone accumulated in the cytoplasm and to a lesser extent in the nucleus. Phosphorylation by
endogenous cellular kinase(s) did not alter the localization of VP22. Co-expression of HSV-2 VP22 with active UL13, but not with
enzymatically inactive UL13, resulted in nuclear accumulation of VP22 and altered nuclear morphology. Surprisingly, redistribution of VP22
to the nucleus occurred independently of UL13-induced phosphorylation of VP22. The altered nuclear morphology of UL13-expressing cells
was not due to apoptosis. These results demonstrate that phosphorylation of HSV-2 VP22 at multiple serine residues is induced by UL13 and
cellular kinase(s), and that the nuclear/cytoplasmic distribution of VP22 is independent of its phosphorylation status but is controlled
indirectly by UL13 kinase activity.
D 2004 Elsevier Inc. All rights reserved.
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Herpes simplex virus (HSV) VP22 is a tegument
phosphoprotein whose function is unknown. Phosphoryla-
tion of VP22 is highly regulated during the virus lifecycle.
Cotranslational phosphorylation of VP22 is followed by
gradual dephosphorylation prior to its incorporation into the
nascent tegument (Geiss et al., 2001). HSV-1 VP22 is
phosphorylated in transfected cells by cellular kinase(s).0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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sity School of Medicine, St. Louis, MO 63110.Phosphorylation occurs at a cluster of three serines in
Casein kinase II (CKII) consensus recognition motifs
(Elliott et al., 1999), and CKII phosphorylates HSV-1
VP22 in vitro (Elliott et al., 1996, 1999; Morrison et al.,
1998). An unidentified cellular VP22-associated kinase
(VAK) also phosphorylates immunoprecipitated HSV-1
VP22 in vitro near its carboxy-terminus (Elliott et al.,
1999), but whether this occurs in cells has not been
determined. HSV itself regulates VP22 phosphorylation.
VP22 is hypophosphorylated in cells infected with HSV-1
that lacks the UL13 viral kinase (Coulter et al., 1993; Geiss
et al., 2001; Overton et al., 1994; Purves and Roizman,
1992), suggesting regulation by UL13. The UL13-depen-
dent phosphorylation sites on VP22 are not known.
Phosphorylation is a common mechanism by which the
function and localization of proteins is controlled. UL13-004) 74–81
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with its efficient dissociation from the tegument (Morrison
et al., 1998), and phosphorylation apparently controls
subcellular distribution of HSV-1 VP22 because only
phosphorylated form(s) are localized in the nucleus during
infection (Pomeranz and Blaho, 1999). Localization of
HSV-1 VP22 to the nucleus occurs in the absence of other
viral gene products (Kotsakis et al., 2001), suggesting that
phosphorylation by cellular kinase(s) may be sufficient to
direct nuclear accumulation of VP22. Additional VP22
activities potentially influenced by phosphorylation include
association with VP16, microtubules, or chromatin (Elliott
and O’Hare, 1998, 2000; Elliott et al., 1995; Pomeranz and
Blaho, 1999). Therefore, a detailed understanding of how
VP22 is phosphorylated by cellular and viral kinases may
help decipher roles of VP22 in the virus replication cycle.
Phosphorylation of VP22 in infected cells is complex.
Both HSV-1 and HSV-2 VP22 appear as a single isoform in
SDS-PAGE of lysates from transfected cells (Elliott et al.,
1996; Geiss et al., 2001). One to three isoforms of HSV-1
VP22 are distinguishable in infected cells (Elliott et al.,
1996; Kotsakis et al., 2001; Pomeranz and Blaho, 1999),
whereas three isoforms of VP22 (termed A, C, and D) can
be resolved from HSV-2-infected cells (Geiss et al., 2001).
These isoforms are distinct from the single isoform (B)
found in transfected cells (Fig. 1C). The two major
phosphoisoforms found in infected cells (C and D) appear
coincident with VP22 synthesis. VP22 is then gradually
dephosphorylated to the hypophosphorylated A isoform thatFig. 1. Potential HSV VP22 phosphorylation sites. (A) Distribution of poten
phosphorylation sites are grouped in three discrete clusters. Cluster II was originally
site mutants. (C) Western blot identification of HSV-2 VP22 isoforms in pcDNA-
22–3 (reproduced from Journal of Virology, with permission).is packaged into virions (Geiss et al., 2001). The C and D
isoforms of HSV-2 VP22 are generated when VP22 is co-
expressed with the UL13 viral kinase in the absence of other
viral gene products. Thus, HSV-2 VP22 phosphorylation
during infection is partially dependent on UL13. The
location of phosphorylation sites on HSV-2 VP22 resulting
in the different isoforms and the kinase-mediating phos-
phorylation at each site in cells is not known. In this report,
we identify the sites on HSV-2 VP22 that are phosphory-
lated via cellular kinases and the UL13 viral kinase. We then
determine the effects of phosphorylation on the subcellular
distribution of VP22.Results
HSV-2 VP22 is phosphorylated by cellular kinases
predominantly at serine residues 70–72
HSV-1 VP22 is reportedly phosphorylated in two
clusters of serine residues. Cluster II (Fig. 1A) contains
serines at residues 71, 72, and 73 in overlapping CKII
consensus sites. This cluster is phosphorylated in vitro by
CKII (Elliott et al., 1999). Cluster III contains two serines
(residues 292 and 294) that are phosphorylated in vitro by
an unknown cellular kinase referred to as VP22-associated
kinase (VAK) (Elliott et al., 1999). An additional CKII
recognition site is found at serine 35 (cluster I), but
phosphorylation of this residue has not been observed. Alltial serine phosphorylation sites on HSV-1 and HSV-2 VP22. Potential
identified in HSV-1 (Elliott et al., 1999). (B) HSV-2 VP22 phosphorylation
VP22 transfected (lane 1) and HSV-2-infected (lane 2) cells using antibody
Fig. 3. UL13 induces phosphorylation of HSV-2 VP22 cluster I. Vero cells
were transfected with expression plasmids for the HSV-2 VP22 phosphory-
lation site mutants in combination with pSG5 or pSG5-UL13. At 24-h
post-transfection, cells were lysed in RIPA, proteins were resolved by
SDS-PAGE, and VP22 was detected by Western blot using 22–3.
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additional CKII consensus site is found at serine 28 in
cluster I (Fig. 1A).
To determine which HSV-2 VP22 serine cluster(s) are
phosphorylated by cellular kinases in cells, we constructed
a series of plasmids that express VP22 in which the serines
in clusters I, II, or III were replaced with alanines (Fig.
1B). Vero cells were transfected with wild-type or mutant
constructs and cell lysates were analyzed by Western blot
for VP22 (Fig. 2). Wild-type VP22 was found in the B
isoform (Fig. 2, lane 1) (Geiss et al., 2001), which was
phosphorylated because it was sensitive to calf intestinal
alkaline phosphatase (CIAP) treatment (Fig. 2, lane 7). The
VP22 SSA mutant (cluster III; VAK sites ablated) was also
found in the B isoform (Fig. 2, lane 2), indicating that
phosphorylation of HSV-2 VP22 to the B isoform in intact
cells does not involve phosphorylation at cluster III. When
the serines in cluster II were mutated, only the A isoform
was observed (SAS; Fig. 2, lane 3). Cellular kinases also
did not efficiently phosphorylate HSV-2 VP22 at cluster I
serines because cells expressing VP22 ASS produced
VP22 in the B isoform (Fig. 2, lane 4). Ablation of the
serines in clusters II and III together (SAA), or in clusters
I, II, and III (AAA) resulted in production of the A
isoform (Fig. 2, lanes 5 and 6), and the SAS mutant was
not sensitive to CIAP (Fig. 2, compare lanes 3 and 8).
These results indicate that serines in cluster II were
phosphorylated by cellular kinases and confirm that the
VAK sites were not utilized. Thus, HSV-2 VP22 expressed
by transient transfection is phosphorylated by cellular
kinases at serine residues in cluster II (positions 70–72),
but not significantly in cluster I (residues 28/34) or cluster
III (residues 291/293).
UL13 induces phosphorylation of VP22 at cluster I
We previously showed that the HSV-2 UL13 kinase
induces phosphorylation of HSV-2 VP22 when the proteins
are co-expressed, and that US3 does not induce phosphor-
ylation of VP22 (Geiss et al., 2001). To determine the sites
on VP22 at which UL13 induces phosphorylation, Vero cells
were transfected with pSG5 or pSG5-UL13 in combination
with plasmids expressing wild-type HSV-2 VP22 or theFig. 2. Phosphorylation of HSV-2 VP22 by cellular kinases. Vero cells were
transfected with plasmids expressing the HSV-2 VP22 phosphorylation site
mutants diagrammed in Fig. 1B (lanes 1–6). At 24-h post-transfection, cells
were lysed in RIPA and selected samples were treated with 10 U CIAP for
30 min at 37 8C (lanes 7 and 8). Proteins were resolved by SDS-PAGE and
VP22 was detected by Western blot using 22–3. The band below the VP22
A isoform (lanes 3 and 5–8) is a cellular protein that cross-reacts with
antibody 22–3 because it is also found in mock lysates.serine-to-alanine VP22 mutants. Wild-type VP22 (SSS) co-
expressed with UL13 was present in the D and C isoforms
(Fig. 3A, lane 2). Mutation of serine cluster I prevented
phosphorylation of VP22 to the C and D isoforms in the
presence of UL13 (Fig. 3A lane 4), but mutation of serine
cluster III did not (Fig. 3B, lane 2), indicating that UL13-
induced kinase activity targets serine residues 28 and/or 34
of HSV-2 VP22. Mutation of the cellular kinase phosphor-
ylation site(s) at serine cluster II increased the mobility of
VP22 in cells transfected with pSG5 or pSG5-UL13 due to
lack of phosphorylation by cellular kinases (Fig. 2, lane 3);
however, VP22 SAS could still be phosphorylated in the
presence of UL13 (Fig. 3A, lane 6). Mutation of serine
cluster III in addition to cluster II did not alter phosphor-
ylation of VP22 in the presence of UL13 (Fig. 3B, lane 4).
These results indicate that UL13 induces phosphorylation of
serine 28 and/or 34 independently of phosphorylation at the
cluster of serine residues 70–72, and that the putative VAK
sites in HSV-2 VP22 are not phosphorylated by cellular
kinases or UL13 in transfected cells.
Because mutation of HSV-2 VP22 serines 28 and 34 to
alanine ablated UL13-mediated phosphorylation of VP22,
we mutated these serine residues independently to deter-Fig. 4. UL13 induces phosphorylation of HSV-2 VP22 at serines 28 and 34.
Vero cells were transfected with pcDNA-VP22 SSS (lanes 1 and 5),
pcDNA-VP22 S28A (lanes 2 and 6), pcDNA-VP22 S34A (lanes 3 and 7),
or pcDNA-VP22 S28A/S34A (lanes 4 and 8) in combination with pSG5-
UL13 (lanes 1–4) or pSG5-UL13 (K176A) (lanes 5–8). At 24 h post-
transfection, cells were lysed in RIPA, proteins were resolved by SDS-
PAGE, and VP22 was detected by Western blot using 22–3.
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found in both the D and C isoforms when coexpressed with
UL13 (Fig. 4, lane 1). The S28A and the S34A single
mutants were each found in the C isoform when UL13 was
present (Fig. 4, lanes 2 and 3), and the S28A/S34A (ASS)
double mutant yielded the B isoform (Fig. 4, lane 4). These
results indicate that phosphorylation of serine residues 28
and 34 can be independently induced by UL13, and they
imply that the D isoform results from phosphorylation at
both S28 and S34. pSG5-UL13(K176A), a derivative of
pSG5-UL13, contains a lysine-to-alanine mutation at
position 176 of UL13 that is critical for serine/threonine
kinase activity (Smith and Smith, 1989). When pSG5-
UL13(K176A) was cotransfected with any of the VP22
constructs containing serine-to-alanine mutations at posi-
tions 28 and/or 34, VP22 migrated predominantly in the B
isoform (Fig. 4, lanes 5–8), demonstrating that the kinase
activity of UL13 is necessary for efficient generation of the
D and C isoforms of VP22.Fig. 5. UL13 kinase activity induces nuclear accumulation of VP22. Vero cells wer
VP22 AAA (Panels C, D, G, and H) plus pSG5-UL13(K176A) (Panels A
immunofluorescence. pcDNA-VP22 SSS was also transfected into cells alone an
5K). Magnification: panels A–H, 100 objective; panel I, 40 objective; panelsUL13 directs VP22 to the nucleus independently of VP22
phosphorylation
Phosphorylation of HSV-1 VP22 was previously reported
to influence its subcellular localization (Pomeranz and
Blaho, 1999). To determine whether phosphorylation is
sufficient to direct HSV-2 VP22 to the nucleus, we co-
expressed VP22 SSS or AAA with UL13 or UL13(K176A)
and localization of VP22 was examined by immunofluor-
escence microscopy (Fig. 5). Wild-type VP22 SSS
expressed alone (Figs. 5I–K) or in the presence of
UL13(K176A) (Figs. 5A and B) displayed VP22 staining
in the nucleus and on filamentous cytoplasmic structures
that co-stained with h-tubulin-specific antibody (Figs. 5J
and K). Individual cells shown were highly representative
(Fig. 5I, low magnification). VP22 AAA (clusters I, II, and
III mutated) expressed in the presence of UL13(K176A)
(Figs. 5C and D) showed an intracellular distribution very
similar to wild-type VP22 (Figs. 5A and B), indicating thate co-transfected with pcDNA-VP22 SSS (Panels A, B, E, and F) or pcDNA-
to D) or pSG5-UL13 (Panels E to H) and VP22 was detected by
d VP22 and h-tubulin were detected by immunofluorescence (Panels 5I to
J and K, 100 objective.
Fig. 6. Vero cells expressing HSV-2 UL13 do not undergo apoptosis. Vero
cells were transfected with pBSH1-LacZ in combination with empty vector,
pSG5-UL13, pSG5-UL13(K176A), or pCMV-HA-Bik. At 24 h post-
transfection, lacZ-expressing cells were detected by staining with X-gal and
were visualized by light microscopy. Positive cells were counted by random
selection of 12 fields-per-well. The experiment was done in duplicate.
* Indicates no positive cells in any of the fields counted.
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influence the distribution of VP22 in transfected cells. Co-
expression of VP22 SSS or VP22 AAAwith UL13 resulted
in the accumulation of VP22 almost exclusively in the
nucleus (Figs. 5E–H). We also observed that the nuclei in
pSG5-UL13-transfected cells were malformed, reminiscent
of nuclear alterations associated with apoptosis.
Because UL13 reportedly induces apoptosis (Hagglund
et al., 2002), we determined whether the accumulation of
VP22 in the nucleus of VP22 and UL13-expressing Vero
cells was a result of apoptosis. Vero cells were transfected
with lacZ-expressing plasmid pBSH1-LacZ in combination
with pSG5-UL13 or pSG5-UL13(K176A). As a positive
control for apoptosis, cells were transfected with pBSH1-
LacZ in combination with Bik-expressing plasmid pCMV-
HA-Bik. Our virtually identical results at 16 and 24 h post-
transfection (Fig. 6) indicate that Bik expression resulted in
apoptosis in Vero cells, ablating lacZ expression. In contrast,
LacZ was expressed when cells were transfected with
pBSH1-LacZ in combination with empty vector, pSG5-
UL13, or pSG5-UL13(K176A). Thus, UL13-mediated
nuclear accumulation of VP22 apparently is not due to
apoptosis.Discussion
VP22 exists in several phosphorylated isoforms during
the course of HSV-2 infection. We previously showed that
these HSV-2 VP22 phosphoisoforms are generated in the
presence of cellular kinase(s) and the UL13 viral kinase
(Geiss et al., 2001). Our current analysis of sites
phosphorylated on HSV-2 VP22 in cells reveals both
similarities and differences with the pattern previously
established for HSV-1 VP22 (Elliott et al., 1996, 1999).Like its HSV-1 counterpart, HSV-2 VP22 is phosphorylated
by cellular kinases at a cluster of three overlapping CKII
sites (cluster II). In contrast to HSV-1 VP22, phosphor-
ylation of HSV-2 VP22 does not occur at VAK sites
(cluster III). Also unlike HSV-1 VP22, we have identified
two serine residues on HSV-2 VP22 that are phosphory-
lated in the presence of UL13 (cluster I). We did not find
evidence for direct phosphorylation of VP22 by UL13
using an in vitro kinase assay (data not shown), suggesting
that UL13 may activate a cellular kinase to phosphorylate
VP22 at serines 28 and 34 in cluster I. Taken together, our
observations reveal the basis for the various phosphorylated
isoforms of HSV-2 VP22.
Potential phosphorylation sites on HSV-2 VP22 are
largely conserved on HSV-1 VP22. VP22 serines in cluster
II are conserved between HSV-1 and HSV-2 (residues 71–
73 and 70–72, respectively), and we demonstrate here that
phosphorylation of this cluster by cellular kinase(s) is also
conserved. Our observation that HSV-2 VP22 is phosphory-
lated in cells at serines 28 and 34 (cluster I) is novel. Only
one of these serines (residue 35) is conserved in HSV-1
VP22, and phosphorylation at this site has not been
demonstrated.
Our data show that phosphorylation of HSV-2 VP22 at
serines 28 and 34 (cluster I) is primarily mediated by the
viral kinase UL13 in cotransfected cells. HSV-2 VP22
serines 28 and 34 also can be modified by cellular kinase(s)
at low levels because a small amount of wild-type VP22 is
modified to the C isoform in the absence of UL13 kinase
activity (Fig. 3, lane 1, and Fig. 4, lanes 5–7). Our results
indicate that UL13 kinase activity greatly augments this
weak cellular kinase activity. Serines 28 and 34 each could
be independently phosphorylated through the action of
UL13 (Fig. 4). Previous labeling experiments had demon-
strated that HSV-1 VP22 is hypophosphorylated in lysates
of cells infected with UL13-deficient mutants of HSV-1
(Coulter et al., 1993; Overton et al., 1994; Purves and
Roizman, 1992) but the site(s) of UL13-mediated phosphor-
ylation of VP22 had not been identified. We do not know
whether HSV-1 VP22 is phosphorylated through the action
of UL13, in particular at conserved serine 35, and evidence
for UL13-mediated phosphorylation of HSV-1 VP22
remains controversial (Elliott et al., 1996; Morrison et al.,
1998; Overton et al., 1994).
We were unable to detect phosphorylation of HSV-2
VP22 at serine residues 292/294 (cluster III). We had
expected that VAK phosphorylation identified in HSV-1
VP22 [cluster III; (Elliott et al., 1999)] would also occur in
HSV-2 VP22 because the sequence surrounding the VAK-
phosphorylated serines is completely conserved. This differ-
ence between HSV-1 and HSV-2 phosphorylation may be
explained in three ways. First, it is possible that the VAK
interacts appropriately with HSV-1 VP22 but not HSV-2
VP22 because of sequence differences at distant locations.
Second, the kinase responsible for phosphorylation of VP22
at the VAK sites may be active only in certain cell types.
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transfected COS-1 cells, whereas we assessed VAK phos-
phorylation of HSV-2 VP22 in Vero cells. Third, the
techniques used in investigation of HSV-1 and HSV-2
phosphorylation at cluster III differed. We detected phos-
phorylation as a mobility shift of VP22 in lysates by
Western blot whereas HSV-1 VP22 phosphorylation was
detected by analysis of immunoprecipitated HSV-1 VP22;
immunoprecipitation may have altered the conformation of
the protein, making the VAK sites accessible to a co-
precipitating kinase. Regardless of the reason, HSV-2 VP22
serine residues 292 and 294 do not appear to be
phosphorylated in intact cells.
The phosphorylation status of HSV-1 VP22 correlates
with its subcellular distribution by biochemical fractionation
(Pomeranz and Blaho, 1999), and HSV-1 VP22 expressed in
the absence of other viral gene products localizes exclu-
sively to the nucleus (Kotsakis et al., 2001). We noted
several interesting differences between HSV-1 and HSV-2
VP22 phosphorylation and intracellular location. First, we
determined that HSV-2 VP22 expressed alone occurs in
both cytoplasm and nucleus, in contrast to the nuclear
location of HSV-1 VP22. Cytoplasmic HSV-2 VP22 is not
the result of seepage from the nucleus because cells were
fixed with paraformaldehyde followed by methanol, a
procedure that completely fixes the cells and so reflects
accurate distribution of the proteins within them (Kotsakis et
al., 2001). Second, we determined that mutation of all serine
phosphorylation sites within HSV-2 VP22 clusters I, II, and
III (AAA) does not alter the intracellular localization of the
protein in transfected cells. This result implies that HSV-2
VP22 localization to the nucleus is independent of
phosphorylation by cellular kinases. Third, co-expression
of either HSV-2 VP22 or VP22 (AAA) with UL13 results in
nuclear localization of VP22 via a mechanism independent
of VP22 phosphorylation. UL13 kinase activity is essential
for this redistribution because ablation of its kinase activity
abrogates the effect (Fig. 5).
We have noted alteration of nuclear morphology in
UL13-transfected cells, but not UL13(K176A)-transfected
cells. Previous studies suggest that baculovirus-expressed
HSV-1 UL13 activates caspase-3, a key apoptotic factor
(Hagglund et al., 2002). Thus, we originally surmised that
VP22 redistribution was a consequence of UL13-induced
apoptosis, which would activate myriad pathways influenc-
ing protein distribution as well as dramatically alter the
morphology of the nucleus. However, we did not observe
apoptotic markers in UL13-expressing Vero cells other than
altered nuclear morphology. It is possible that HSV-1 UL13
induces caspase-3 activation, but HSV-2 UL13 does not,
and the caspase activation could facilitate replication rather
than apoptosis. Activation of caspases for the purpose of
cleaving specific viral proteins occurs in the replication
cycle of some viruses (Best and Bloom, 2004). Alterna-
tively, the data supporting a role for HSV-1 UL13 in
induction of apoptosis may result from UL13 interactionwith baculovirus-induced factors that are not present in
mammalian cells.
Because apoptosis is not involved in UL13-mediated
HSV-2 VP22 nuclear localization and because other
phosphorylated states of VP22 itself do not affect the
localization of VP22, it seems likely that UL13 alters the
cellular nuclear transport machinery or that UL13 kinase
activity alters the integrity of the nuclear envelope. Through
either mechanism, VP22 may enter and be retained in the
nucleus, possibly by binding to chromatin (Knopf and
Kaerner, 1980). Altered nuclear morphology also occurs as
cells approach mitosis, and HSV drives cells to the G2/M
interface (Advani et al., 2000). Cell cycle progression to G2/
M requires the activity of cdc2 (Draetta and Beach, 1988;
Nigg, 1995) and cdc2 is activated in HSV-infected cells
(Advani et al., 2000). HSV-1 UL13 was recently shown to
phosphorylate a serine residue within a cdc2 kinase
consensus motif (Kawaguchi et al., 2003). Therefore, we
hypothesize that HSV UL13 may act like a cdc2 kinase or
activate a cdc2-like kinase to phosphorylate VP22.
The function of VP22 phosphorylation induced by UL13
or cellular kinases is not known, but certain lines of
evidence offer clues. VP22 packaged into the tegument is
hypophosphorylated (Geiss et al., 2001), and UL13-induced
phosphorylation of VP22 correlates with efficient tegument
disaggregation (Morrison et al., 1998). Once dispersed from
the tegument, the VP22 phosphorylation state may influence
VP22 association with cellular or viral binding partners such
as VP16 or NMIIA (Elliott et al., 1995; van Leuwen et al.,
2002). UL13-mediated regulation of VP22 phosphorylation
suggests an important function of VP22 during virus
replication, and our identification of phosphorylation sites
on HSV-2 VP22 may help elucidate this role.Materials and methods
Cells
Vero cells were maintained in Dulbecco’s modified Eagle
medium (DMEM) supplemented with 3% fetal calf serum
and 3% newborn calf serum, baby hamster kidney (BHK)
cells were grown in DMEM supplemented with 5% fetal
calf serum and 5% newborn calf serum.
Plasmids
Plasmid pcDNA-VP22(2) contains the UL49 open read-
ing frame from HSV-2 strain 186 inserted into pcDNA3.1
(Invitrogen). pSG5-US3 and pSG5-UL13 contain the HSV-
2 strain 186 US3 and UL13 open reading frames,
respectively, cloned into pSG5 (Stratagene). PSG5-
UL13(K176A) is a derivative of pSG5-UL13 containing a
lysine-to-alanine mutation at position 176. pCMV-HA-Bik
contains the Bik open reading frame inserted into
pcDNA3.1 (Invitrogen). pBSH1-LacZ contains the lacZ
B.J. Geiss et al. / Virology 330 (2004) 74–8180open reading frame cloned into the pBS vector (Stratagene).
PCR-based site-directed mutagenesis was used to alter
amino acid coding sequences. Mutated plasmids were
verified by sequencing. Transfections were performed using
Lipofectamine (Invitrogen) according to the manufacturer’s
recommendations.
Antibodies
The mouse monoclonal antibody 22–3, specific for HSV
VP22, was described previously (Geiss et al., 2001).
Antibody 22–3 used for immunofluorescence analyses was
coupled to Alexa 488 (Molecular Probes) according to the
manufacturer’s instructions. Cy3-conjugated anti-h-tubulin
monoclonal antibody (Sigma) was also used.
Western blot analysis
Whole cell lysates were solubilized in RIPA [1% Triton
X-100, 1% sodium deoxycholate, 0.1% SDS, 150 mM
NaCl, 20 mM Tris–HCl (pH 7.4)] supplemented with 2 Ag/
ml aprotinin, 3 Ag/ml leupeptin, and 1 mM phenyl-
methylsulfonyl fluoride. Proteins were resolved by SDS-
PAGE and transferred to polyvinylidene difluoride (PVDF)
membranes. VP22 was bound by antibody 22–3 and
detected with alkaline phosphatase-conjugated secondary
antibodies and NBT/BCIP (Promega), or streptavidin
peroxidase-conjugated antibodies and ECL-Plus (Amer-
sham Biosciences).
Immunofluorescence
Vero cells were seeded onto glass coverslips and trans-
fected 24 h later with 1 Ag of plasmid DNA (or 0.5 Ag of
each DNA for cotransfections). At 16-h post-transfection,
the cells were washed once with PBS and fixed with 3.7%
paraformaldehyde at room temperature for 20 min, followed
by ice-cold methanol for 20 min. Cells were subsequently
washed five times with PBS and incubated with fluores-
cently labeled primary antibody in PBS containing 1%
bovine serum albumin (Sigma) for 1 h, then washed five
times with PBS and mounted onto glass slides. Fluorescence
was visualized on a Nikon Optiphot-2 fluorescence micro-
scope and the images were captured digitally.
LacZ expression assay
Vero cells cultured in 6-well plates were transfected with
pBSH1-LacZ in combination with empty vector (pSG5),
pSG5-UL13, pSG5-UL13(K176A), or pCMV-HA-Bik. At
16 or 24 h post-transfection, cells were washed once with
PBS and fixed with 3.7% paraformaldehyde at room
temperature for 7 min. The paraformaldehyde was removed
and X-gal (0.75% in PBS containing 1.5 mM MgCl2, 3.7
mM potassium ferrocyanide, and 3.7 mM potassium
ferricyanide) was added to the cells for 1 h at 37 8C. Bluecells (expressing lacZ) were visualized by light microscopy.
Positive cells were counted in 12 arbitrarily selected fields
equally distributed in each well.Acknowledgments
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